Plain-English translation of NCT06832202 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two medications — and — for people with a particular type of advanced breast cancer called HER2-low, hormone receptor positive breast cancer. These are patients whose cancer has either spread beyond the breast or has worsened despite standard treatment. Researchers want to see if giving these two medications together can help slow or stop the cancer's growth.
Many people with this type of breast cancer don't have good treatment options when standard therapies stop working or cause unbearable side effects. This study is exploring whether the medication combination might be more effective for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would receive injections of both medications intravenously (through a vein) once every three weeks. The study involves 50 participants total, and you would continue treatment as long as the medication is helping and you can tolerate the side effects. You'll have regular visits for blood tests, scans, and check-ins with your care team to monitor how you're responding and manage any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China